This is a prospective, multicenter, randomized, uncontrolled Phase II study to assess the efficacy and safety of adebrelimab in combination with chemotherapy with or without bevacizumab for the treatment of resectable Stage II-IIIB (T3N2) NSQ-NSCLC and to explore biomarkers associated with efficacy.
Resectable NSQ NSCLC
Age 18-65 years
male or female
ECOG 0-1
SCLC or SQ NSCLC
previously used anti-PD1, anti-PDL1, anti-CTLA4 antibodies, etc.
patients who have previously used anti-angiogenic drugs;
allergic to any component of the study drug or chemotherapy drugs
The First Affiliated Hospital of Guangzhou Medical University
Lead sponsor